Fig. 1S
1 H NMR (CDCl 3 , 400 MHz) spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 2S
13 C NMR (CDCl 3 , 100 MHz) spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 3S COSY spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).

Fig. 4S HMQC spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 5S
HMBC spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 6S
NOESY spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 7S
Mass spectrum of 28-O-acetyl-3-O-trans-caffeoylbetulin (1).
Fig. 8S
1 H NMR spectrum (1:10 CD 3 OD/CDCl 3 , 400 MHz) of 3α-O-trans-p-coumaroyl-22-hydroxyhopane (2).
Fig. 9S
13 C NMR spectrum (1:10 CD 3 OD/CDCl 3 , 400 MHz) of 3α-O-trans-p-coumaroyl-22-Hydroxyhopane (2). 
Fig. 15S
1 H NMR spectrum(1:10 CD 3 OD/CDCl 3 , 400 MHz) of 3α-O-cis-p-coumaroyl-22-Hydroxyhopane (3).
Fig. 16S
13 C NMR spectrum (1:10 CD 3 OD/CDCl 3 , 100 MHz) of 3α-O-trans-p-coumaroyl-22-Hydroxyhopane (3). 
Fig. 29S
1 H NMR spectrum of 3α-3,22-dihydroxyhopane (CDCl 3 , 400 MHz).
Fig. 30S
13 C NMR spectrum (CDCl 3 , 100 MHz) of 3α-3,22-dihydroxyhopane.
Fig. 31S
Dose-response curve of KB activity assay for compound 4 KB. 
Table 1S
Antimalarial activity assay of compound 6.
* Three concentrations of testing compound were treated with P. falciparum and then two concentrations that exhibited 50% growth inhibition were selected to calculate an IC50 by using the following formula:
where, C1 is concentration of sample with parasite inhibition ≥ 50%, C2 is concentration of sample with parasite inhibition < 50%, i1 is percentage of parasite inhibition at C1, i2 is percentage of parasite inhibition at C2. 
